Oncovirus

An oncovirus is a virus that can cause cancer. This term originated from studies of acutely-transforming retroviruses in the 1950–60s, often called oncornaviruses to denote their RNA virus origin. It now refers to any virus with a DNA or RNA genome causing cancer and is synonymous with "tumor virus" or "cancer virus". The vast majority of human and animal viruses do not cause cancer, probably because of long-standing coevolution between the virus with its host.

Worldwide, the WHO International Agency for Research on Cancer estimated that in 2002 17.8% of human cancers were caused by infection, with 11.9% being caused by one of seven different viruses.^[1] The importance of this is that these cancers might be easily prevented through vaccination (e.g., papillomavirus vaccines), diagnosed with simple blood tests, and treated with less-toxic antiviral compounds.

Background

Generally, tumor viruses cause little or no disease after infection in their hosts, or cause non-neoplastic diseases such as acute hepatitis for hepatitis B virus or mononucleosis for Epstein-Barr virus. A minority of persons (or animals) will go on to develop cancers after infection. This has complicated determining whether or not a given virus causes cancer. The well-known Koch's Postulates, are 19th Century constructs developed by Robert Koch to establish the likelihood for Bacillus anthracis causing anthrax disease and are not applicable to viral diseases (Firstly, viruses cannot truly be isolated in pure culture - even stringent isolation techniques cannot exclude undetected contaminating viruses with similar density characteristics and viruses must be grown on cells. Secondly, asymptomatic virus infection and carriage is the norm for most tumor viruses, which violates Koch's third principle. Relman and Fredericks have elegantly described the difficulties in using Koch's postulates to virus-induced cancers.^[2] Finally, the host restriction for human viruses makes it unethical to experimentally transmit a suspected cancer virus.) Thus, other measures such as A.B. Hill's criteria^[3] are more relevant to cancer virology but also face some difficulties in determining causality.

Tumor viruses come in a variety of forms: viruses with a DNA genome, such as adenovirus, and viruses with an RNA genome, like the Hepatitis C virus (HCV) can cause cancers, as can retroviruses having both DNA and RNA genomes (Human T-lymphotropic virus and hepatitis B virus, which normally replicates as a mixed double and single-stranded DNA virus but also has a retroviral replication component). In many cases, tumor viruses do not cause cancer in their native hosts but only in dead-end species. For example, adenoviruses do not cause cancer in humans but are instead responsible for colds, conjunctivitis and other acute illnesses. They only become tumorigenic when infected into certain rodent species, such as Syrian hamsters. Some viruses are tumorigenic when they infect a cell and persist as circular episomes or plasmids, replicating separately from host cell DNA (Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus). Other viruses are only carcinogenic when they integrate into the host cell genome as part of a biological accident, such as polyomaviruses and papillomaviruses.

A direct oncogenic viral mechanism^[4] involves either insertion of additional viral oncogenic genes into the host cell or to enhance already existing oncogenic genes (proto-oncogenes) in the genome. Indirect viral oncogenicity involves chronic nonspecific inflammation occurring over decades of infection, as is the case for HCV-induced liver cancer. These two mechanisms differ in their biology and epidemiology: direct tumor viruses must have at least one virus copy in every tumor cell expressing at least one protein or RNA that is causing the cell to become cancerous. Because foreign virus antigens are expressed in these tumors, persons who are immunosuppressed such as AIDS or transplant patients are at higher risk for these types of cancers. Chronic indirect tumor viruses, on the other hand, can be lost (at least theoretically) from a mature tumor that has accumulated sufficient mutations and growth conditions (hyperplasia) from the chronic inflammation of viral infection. In this latter case, it is controversial but at least theoretically possible that an indirect tumor virus could undergo "hit-and-run" and so the virus would be lost from the clinically diagnosed tumor. In practical terms, this is an uncommon occurrence if it does occur.

Timeline of Discovery

• 1908: Oluf Bang and Vilhelm Ellerman, University of Copenhagen, first demonstrated that avian leukosis virus could be transmitted after cell-free filtration to new chickens, causing leukemia.
• 1910: Peyton Rous at Rockefeller extended Bang and Ellerman's experiments to show filtrable cell-free transmission of a solid tumor sarcoma to chickens. The reasons why chickens are so receptive to such transmission may involve unusual characteristics of stability or instability as they relate to endogenous retroviruses.^[5]
• 1933: Richard Edwin Shope discovered cottontail rabbit papillomavirus or Shope papillomavirus, the first mammalian tumor virus.
• 1936: Mouse mammary tumor virus shown by John J. Bittner to be an "extrachromosomal factor" (i.e., virus) transmitted among laboratory strains of mice by breast feeding.^[6] This was an extension of work on murine breast cancer caused by a transmissible agent as early as 1915, by A.F. Lathrop and L. Loeb.^[7]
• 1954: Ludwik Gross, working at the Bronx VA medical center isolated murine polyomavirus causing a variety of salivary gland and other tumors in specific strains of newborn mice. This was not widely appreciated until the results were confirmed by scientists at NIH reproducing the experiments under the same conditions.
• 1961: Simian Vacuolating virus 40 (SV40) discovered by Eddy at NIH, and Hillman and Sweet at Merck laboratory as a rhesus macaque virus contaminating cells used to make of Salk and Sabin polio vaccines. Several years later it was shown to cause cancer in Syrian hamsters, raising alarm that persists today. Scientific consensus now strongly agrees that this is not likely to cause human cancer although the controversy still persists.

Human Cancer Viruses

• 1964: Anthony Epstein, Bert Achong and Yvonne Barr identify the first human cancer virus from Burkitt lymphoma cells. A herpesvirus, this virus is formally known as human herpesvirus 4 but more commonly called Epstein-Barr Virus or EBV. Achong, a Trinidadian of Ghanaian ancestry, is frequently forgotten for this work but was central to the electron microscopy that allowed detection.^[8]
• mid-1960s: Baruch Blumberg first physically isolated and characterized Hepatitis B while at NIH and later Fox Chase Laboratory, receiving the 1976 Nobel Prize in Medicine or Physiology.^[9] Although this agent was the clear cause of hepatitis and might contribute to liver cancer hepatocellular carcinoma, this link was not firmly established until epidemiologic studies were performed in the 1980s by R. Palmer Beasley and others.^[10]
• 1980: Human T-lymphotropic virus 1 (HTLV I), the first human retrovirus was discovered by Bernard Poiesz and Robert Gallo^[11][12] at NIH and Mistuaki Yoshida and coworkers in Japan.^[13]
• 1984–86: Harald zur Hausen, together with Lutz Gissman, discovered first HPV16 and then HPV18 responsible for approximately 70% of cervical cancers. For discovery that human papillomaviruses (HPV) cause human cancer, zur Hausen won a 2008 Nobel Prize.^[14]
• 1987: Hepatitis C virus, or HCV, discovered by panning a cDNA library made from diseased tissues for foreign antigens recognized with patient sera. This work was performed by Michael Houghton at Chiron, a biotechnology company, and D.W. Bradley at CDC.^[15] Controversy erupted when Chiron claimed all rights to the discovery although the work had been performed under contract with the CDC using Bradley's materials and ideas. Eventually, this was amicably settled. HCV was subsequently shown to be a major contributor to liver cancer (hepatocellular carcinoma) worldwide.
• 1994: Patrick S. Moore and Yuan Chang (a husband and wife team^[16] then at Columbia University) working together with Frank Lee and Ethel Cesarman^[17] isolated Kaposi sarcoma-associated herpesvirus (KSHV or HHV8) using representational difference analysis. This search was prompted from work by V. Beral, T. Peterman and H. Jaffe who showed from accumulating evidence from the epidemic of Kaposi sarcoma associated with AIDS, that this cancer must have another infectious cause besides HIV itself.^[18] This agent was predicted to be a new virus. Subsequent studies revealed that KSHV is indeed the "KS agent" and is responsible for the epidemiologic patterns of KS and related cancers.^[19]
• 2008: Chang and Moore, now at the University of Pittsburgh Cancer Institute, developed a new method to identify cancer viruses based on computer subtraction of human sequences from a tumor transcriptome, called digital transcriptome subtraction (DTS).^[20] DTS was used to isolate DNA fragments of Merkel cell polyomavirus from a Merkel cell carcinoma and it is now believed that this virus causes 70–80% of these cancers.^[21] This is the first polyomavirus to be well-established as the cause for a human cancer.

History

The theory that cancer could be caused by a virus began with the experiments of Oluf Bang and Vilhelm Ellerman in 1908 who first show that avian erythroblastosis (a form of chicken leukemia) could be transmitted by cell-free extracts. This was subsequently confirmed for solid tumors in chickens in 1910-1911 by Peyton Rous.

By the early 1950s it was known that viruses could remove and incorporate genes and genetic material in cells. It was suggested that these new genes inserted into cells could make the cell cancerous. Many of these viral oncogenes have been discovered and identified to cause cancer.

The main viruses associated with human cancers are human papillomavirus, hepatitis B and hepatitis C virus, Epstein-Barr virus, human T-lymphotropic virus, Kaposi's sarcoma-associated herpesvirus (KSHV) and Merkel cell polyomavirus. Experimental and epidemiological data imply a causative role for viruses and they appear to be the second most important risk factor for cancer development in humans, exceeded only by tobacco usage.^[22] The mode of virally-induced tumors can be divided into two, acutely-transforming or slowly-transforming. In acutely transforming viruses, the viral particles carry a gene that encodes for an overactive oncogene called viral-oncogene (v-onc), and the infected cell is transformed as soon as v-onc is expressed. In contrast, in slowly-transforming viruses, the virus genome is inserted, especially as viral genome insertion is an obligatory part of retroviruses, near a proto-oncogene in the host genome. The viral promoter or other transcription regulation elements in turn cause overexpression of that proto-oncogene, which in turn induces uncontrolled cellular proliferation. Because viral genome insertion is not specific to proto-oncogenes and the chance of insertion near that proto-oncogene is low, slowly-transforming viruses have very long tumor latency compared to acutely-transforming viruses, which already carry the viral oncogene.

Hepatitis viruses, including hepatitis B and hepatitis C, can induce a chronic viral infection that leads to liver cancer in 0.47% of hepatitis B patients per year (especially in Asia, less so in North America), and in 1.4% of hepatitis C carriers per year. Liver cirrhosis, whether from chronic viral hepatitis infection or alcoholism, is associated with the development of liver cancer, and the combination of cirrhosis and viral hepatitis presents the highest risk of liver cancer development. Worldwide, liver cancer is one of the most common, and most deadly, cancers due to a huge burden of viral hepatitis transmission and disease.

Advances in cancer research have made a vaccines designed to prevent cancer. The hepatitis B vaccine is the first vaccine that has been established to prevent cancer (hepatocellular carcinoma) by preventing infection with the causative virus. In 2006, the U.S. Food and Drug Administration approved a human papilloma virus vaccine, called Gardasil. The vaccine protects against four HPV types, which together cause 70% of cervical cancers and 90% of genital warts. In March 2007, the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) officially recommended that females aged 11–12 receive the vaccine, and indicated that females as young as age 9 and as old as age 26 are also candidates for immunization.

Mechanism

Brief history

In the 1960s, the replication process of RNA virus was believed to be similar to other single-stranded RNA. Single-stranded RNA replication involves RNA-dependent RNA synthesis which meant that virus-coding enzymes would make partial double-stranded RNA. This belief was proven to be incorrect because there were no double-stranded RNA found in the retrovirus cell. In the 1964, Howard Temin proposed a provirus hypothesis, but shortly after reverse transcription in the retrovirus genome was discovered.

Description of virus

All retroviruses have three major coding domains; gag, pol and env. In the gag region of the virus, the synthesis of the internal virion proteins are maintained which make up the matrix, capsid and nucleocapsid proteins. In pol, the information for the reverse transcription and integration enzymes are stored. In env, it is derived from the surface and transmembrane for the viral envelope protein. There is a fourth coding domain which is smaller, but exists in all retroviruses. Pol is the domain that encodes the virion protease.

Retrovirus enters host cell

The retrovirus begins the journey into a host cell by attaching a surface glycoprotein to the cell's plasma membrane receptor. Once inside the cell, the retrovirus goes through reverse transcription in the cytoplasm and generates a double-stranded DNA copy of the RNA genome. Reverse transcription also produces identical structures known as long terminal repeats (LTRs). Long terminal repeats are at the ends of the DNA strands and regulates viral gene expression. The viral DNA is then translocated into the nucleus where one strand of the retroviral genome is put into the chromosomal DNA by the help of the virion intergrase. At this point the retrovirus is referred to as provirus. Once in the chromosomal DNA, the provirus is transcribed by the cellular RNA polymerase II. The transcription leads to the splicing and full-length mRNAs and full-length progeny virion RNA. The virion protein and progeny RNA assemble in the cytoplasm and leave the cell, whereas the other copies send translated viral messages in the cytoplasm

Classification

DNA viruses

• Human papilloma virus (HPV), a DNA virus, causes transformation in cells through interfering with tumor suppressor proteins such as p53. Interfering with the action of p53 allows a cell infected with the virus to move into a different stage of the cell cycle, enabling the virus genome to be replicated. Forcing the cell into the S phase of the cell cycle could cause the cell to become transformed.^[23] Some types of HPV increase the risk of, e.g., cervical cancer.
• Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) is associated with Kaposi’s sarcoma, a type of skin cancer.^[24]
• Epstein-Barr virus (EBV or HHV-4) is associated with four types of cancers
• Merkel cell polyomavirus – a polyoma virus – is associated with the development of Merkel cell carcinoma^[21]
• Human cytomegalovirus (CMV or HHV-5) is associated with mucoepidermoid carcinoma and possibly other malignancies.^[25]

RNA viruses

Not all oncoviruses are DNA viruses. Some RNA viruses have also been associated such as the hepatitis C virus as well as human T-lymphotropic virus (HTLV-1).

Overview table

Virus	Percent of cancers[1]	Associated cancer types
Hepatitis viruses, including hepatitis B (HBV) and hepatitis C (HCV)	4.9	Hepatocellular carcinoma (liver cancer).[26][27]
Human T-lymphotropic virus (HTLV)	0.03	Tropical spastic paraparesis and adult T-cell leukemia[28]
Human papillomaviruses (HPV)	5.2	Cancers of cervix,[29] anus,[29] penis,[29] vulva/vagina,[1] and some cancers of the head and neck.[1]
Kaposi’s sarcoma-associated herpesvirus	0.9	Kaposi’s sarcoma, multicentric Castleman's disease and primary effusion lymphoma
Merkel cell polyomavirus	NA	Merkel cell carcinoma
Epstein–Barr virus (EBV)	NA	Burkitt’s lymphoma, Hodgkin’s lymphoma, post-transplantation lymphoproliferative disease and Nasopharyngeal carcinoma.[30]

Estimated percent of new cancers attributable to the virus worldwide in 2002.^[1] NA indicates not available.

See also

• Carcinogen
• Oncogenic
• Oncogene
• Adult T-cell leukemia/lymphoma
• Cancer bacteria
• Oncolytic virus, a virus that infects and kills cancer cells

References

1. ^ ^{a b c d e} Parkin, Donald Maxwell (2006). "The global health burden of infection-associated cancers in the year 2002". International Journal of Cancer 118 (12): 3030. doi:10.1002/ijc.21731. PMID 16404738. 
2. ^ Fredericks DN, Relman DA (January 1996). "Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates". Clinical Microbiology Reviews 9 (1): 18–33. PMC 172879. PMID 8665474. http://cmr.asm.org/cgi/pmidlookup?view=long&pmid=8665474. 
3. ^ Hill AB (May 1965). "The Environment and Disease: Association or Causation?". Proceedings of the Royal Society of Medicine 58: 295–300. PMC 1898525. PMID 14283879. http://www.edwardtufte.com/tufte/hill. 
4. ^ Parsonnet, Julie (1999). Microbes and malignancy: infection as a cause of human cancers. Oxford: Oxford University Press. ISBN 978-0-19-510401-1. ^{[page needed]}
5. ^ Van Epps, Heather L. (February 2005). "Peyton Rous: father of the tumor virus". The Journal of Experimental Medicine 201 (3): 320. doi:10.1084/jem.2013fta. PMC 2213042. PMID 15756727. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2213042. 
6. ^ Bittner JJ (May 1942). "The Milk-Influence of Breast Tumors in Mice". Science 95 (2470): 462–463. doi:10.1126/science.95.2470.462. PMID 17736889. 
7. ^ Lathrop AE, Loeb L (November 1915). "Further Investigations on the Origin of Tumors in Mice: I. Tumor Incidence and Tumor Age in Various Strains of Mice". The Journal of Experimental Medicine 22 (5): 646–673. doi:10.1084/jem.22.5.646. PMC 2125363. PMID 19867946. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2125363. 
8. ^ Epstein MA, Achong BG, Barr YM (March 1964). "Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma". Lancet 1 (7335): 702–3. doi:10.1016/S0140-6736(64)91524-7. PMID 14107961. 
9. ^ "Baruch S. Blumberg - Autobiography". Nobelprize.org. http://nobelprize.org/nobel_prizes/medicine/laureates/1976/blumberg-autobio.html. Retrieved 2010-03-17. 
10. ^ Beasley RP, Hwang LY, Lin CC, Chien CS (November 1981). "Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan". Lancet 2 (8256): 1129–33. doi:10.1016/S0140-6736(81)90585-7. PMID 6118576. 
11. ^ Yoshida, Mitsuaki; Jeang, Kuan-Teh (2005). "Preface to 25 years of HTLV-1 and ATL research". Oncogene 24 (39): 5925. doi:10.1038/sj.onc.1208967. 
12. ^ Gallo RC (September 2005). "History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2". Oncogene 24 (39): 5926–30. doi:10.1038/sj.onc.1208980. PMID 16155599. 
13. ^ Seiki M, Hattori S, Yoshida M (November 1982). "Human adult T-cell leukemia virus: molecular cloning of the provirus DNA and the unique terminal structure". Proceedings of the National Academy of Sciences of the United States of America 79 (22): 6899–902. doi:10.1073/pnas.79.22.6899. PMC 347241. PMID 6294664. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=347241. 
14. ^ "Harald zur Hausen - Autobiography". Nobelprize.org. http://nobelprize.org/nobel_prizes/medicine/laureates/2008/hausen-autobio.html. Retrieved 2010-03-17. 
15. ^ Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (April 1989). "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome". Science 244 (4902): 359–62. doi:10.1126/science.2523562. PMID 2523562. 
16. ^ Schmidt, C. (2008). "Yuan Chang and Patrick Moore: Teaming Up To Hunt Down Cancer-Causing Viruses". Journal of the National Cancer Institute 100 (8): 524. doi:10.1093/jnci/djn122. PMID 18398088. 
17. ^ "Ethel Cesarman, M.D., Ph.D. | Weill Cornell Medical College". Med.cornell.edu. http://www.med.cornell.edu/research/ecesarman/. Retrieved 2010-03-17. 
18. ^ Beral V, Peterman TA, Berkelman RL, Jaffe HW (January 1990). "Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?". Lancet 335 (8682): 123–8. doi:10.1016/0140-6736(90)90001-L. PMID 1967430. 
19. ^ Antman K, Chang Y (April 2000). "Kaposi's sarcoma". The New England Journal of Medicine 342 (14): 1027–38. doi:10.1056/NEJM200004063421407. PMID 10749966. 
20. ^ Feng H, Taylor JL, Benos PV, et al. (October 2007). "Human transcriptome subtraction by using short sequence tags to search for tumor viruses in conjunctival carcinoma". Journal of Virology 81 (20): 11332–40. doi:10.1128/JVI.00875-07. PMC 2045575. PMID 17686852. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2045575. 
21. ^ ^{a b} Feng H, Shuda M, Chang Y, Moore PS (February 2008). "Clonal integration of a polyomavirus in human Merkel cell carcinoma". Science 319 (5866): 1096–100. doi:10.1126/science.1152586. PMC 2740911. PMID 18202256. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2740911. 
22. ^ zur Hausen H (November 1991). "Viruses in human cancers". Science 254 (5035): 1167–73. doi:10.1126/science.1659743. PMID 1659743. 
23. ^ Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (December 1990). "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53". Cell 63 (6): 1129–36. doi:10.1016/0092-8674(90)90409-8. PMID 2175676. 
24. ^ Chang Y, Cesarman E, Pessin MS, et al. (December 1994). "Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma". Science 266 (5192): 1865–9. doi:10.1126/science.7997879. PMID 7997879. 
25. ^ "Melnick M., Sedghizadeh P. S., Allen C. M., Jaskoll T.". Experimental and Molecular Pathology. 10 November 2011. doi:doi:10.1016/j.yexmp.2011.10.011. http://www.sciencedirect.com/science/article/pii/S0014480011001869. 
26. ^ Koike K (June 2007). "Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways". Journal of Gastroenterology and Hepatology 22 Suppl 1: S108–11. doi:10.1111/j.1440-1746.2006.04669.x. PMID 17567457. 
27. ^ Hu J, Ludgate L (2007). "HIV-HBV and HIV-HCV coinfection and liver cancer development". Cancer Treatment and Research 133: 241–52. doi:10.1007/978-0-387-46816-7_9. PMID 17672044. 
28. ^ Bellon M, Nicot C (2007). "Telomerase: a crucial player in HTLV-I-induced human T-cell leukemia". Cancer Genomics & Proteomics 4 (1): 21–5. PMID 17726237. http://cgp.iiarjournals.org/cgi/pmidlookup?view=long&pmid=17726237. 
29. ^ ^{a b c} Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (September 2007). "Human papillomavirus and cervical cancer". Lancet 370 (9590): 890–907. doi:10.1016/S0140-6736(07)61416-0. PMID 17826171. 
30. ^ Klein E, Kis LL, Klein G (February 2007). "Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions". Oncogene 26 (9): 1297–305. doi:10.1038/sj.onc.1210240. PMID 17322915. 

External links

• MeSH Oncoviruses